x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243075
| Product Information | |
|---|---|
| Synonyms | β-NM-d4; NMN-d4 |
| Formula | C11H11D4N2O8P |
| Molecular Weight | 338.24 |
| SMILES | O[C@H]1[C@@H](O)[C@H]([N+]2=C([2H])C([2H])=C([2H])C(C(N)=O)=C2[2H])O[C@@H]1COP(O)([O-])=O |
| Target | Endogenous Metabolite |
| Product Description | β-Nicotinamide mononucleotide-d4 is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to off-white |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years In solvent: -80°C, 6 months; -20°C, 1 month |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
